AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18318696
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice added to 0.75 mg x kg(‐1) midazolam
Trial: 18318696
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice added to 0.75 mg x kg(‐1) midazolam
Trial: 18318696
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg x kg(‐1) midazolam without any additive
Trial: 9527730
Drug: Propofol sedation
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol sedation (5 mg kg(‐1) h(‐1) initially, titrated to 2.4+/‐0.7 mg kg(‐1) h(‐1))
Trial: 7629525
Drug: Aspirin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30 or 283 mg)
Trial: 2799022
Drug: Tiapride (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (7.5 mg/kg)
Trial: 62946
Drug: Rifampicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin plus isoniazid for nine months, supplemented by ethambutol (25 mg/kg for the first two months)
Trial: 30796855
Drug: Exogenous lactase
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous lactase preparation
Trial: 22145355
Drug: 2% acid‐soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% acid‐soluble chitosan solution (200‐250 kDa molecular weight)
Trial: 19628651
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of acylated ghrelin (AG) 100 microg and unacylated ghrelin (UAG) 100 microg (Comb)
Trial: 27272073
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent designed to reduce P. acnes biofilm
Trial: 10822123
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (0.625 mg/day oral conjugated estrogen)
Trial: 10822123
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy with continuous low-dose progestin (2.5 mg oral medroxyprogesterone acetate/day)
Trial: 6405431
Drug: Alcoholic beverage
RxNorm normalized name: Alcoholic beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic beverage (0.50 g/kg body weight)
Trial: 20236248
Drug: ADX10059 125
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX10059 125 mg b.i.d.
Trial: 20236248
Drug: ADX10059 250
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX10059 250 mg b.i.d.
Trial: 17261559
Drug: Eccentric training
RxNorm normalized name: SYRINGE 60ML ECCENTRIC TIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eccentric training (various protocols including drop squats, slow eccentric movement, squatting on decline board or level ground, etc.) for 12 weeks, twice daily.
Trial: 15855570
Drug: INH (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH (6 mg)
Trial: 11997197
Drug: Avinza 30
RxNorm normalized name: Avinza 30mg Extended-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avinza 30 mg once daily
Trial: 11997197
Drug: MS Contin
RxNorm normalized name: MS Contin
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS Contin 15 mg twice daily
Trial: 30107283
Drug: MEDI3902 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3902 (250 mg)
Trial: 30107283
Drug: MEDI3902 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3902 (750 mg)
Trial: 30107283
Drug: MEDI3902 (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3902 (1500 mg)
Trial: 30107283
Drug: MEDI3902 (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3902 (3000 mg)
Trial: 29943364
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment (100 mg/day)
Trial: 1936422
Drug: Omnipaque 350
RxNorm normalized name: Omnipaque 350
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omnipaque 350 (75.49% iohexol, 350 mgI ml‐1)
Trial: 1936422
Drug: Angioconray (80%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angioconray (80% sodium iothalamate, 480 mgI ml‐1)
Trial: 28585735
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg green tea extract, two capsules/day
Trial: 28585735
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg starch, two capsules/day
Trial: 24993562
Drug: SINGLE (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SINGLE (once daily training)
Trial: 24993562
Drug: REPEATED (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REPEATED (twice every second day training)
Trial: 21372694
Drug: Amlodipine/valsartan (5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (5/160 mg) in the morning
Trial: 21372694
Drug: Amlodipine/valsartan (5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (5/160 mg) in the evening
Trial: 21372694
Drug: Amlodipine/valsartan (10/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (10/160 mg) after uptitration if needed
Trial: 15380292
Drug: Cocaine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (150 mg)
Trial: 9701103
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine (10-40 mg/d), possibly combined with enalapril maleate (5-20 mg/d) and/or hydrochlorothiazide (12.5-25 mg/d)
Trial: 8149523
Drug: Clinical and
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and biochemical variables (age, previous treatment for systemic hypertension, presence of clinical heart failure, plasma atrial natriuretic factor levels)
Trial: 16351387
Drug: Daily Abstinence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Abstinence Self-Efficacy (ASE)
Trial: 2190851
Drug: Pentasa (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa (1.5 g daily)
Trial: 2190851
Drug: Placebo (dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dummy tablet)
Trial: 7438324
Drug: Cystectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystectomy plus preoperative irradiation (6.5 Gy X 2F/1 week) with misonidazole (3 g/m2, two doses, orally)
Trial: 7438324
Drug: Cystectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystectomy plus preoperative irradiation (4.0 Gy X 5F) with misonidazole (2 g/m2)
Trial: 7438324
Drug: Split course
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split course (SC) protracted regime with misonidazole (0.5 g/m2 daily doses, total dose 14 g/m2 over 61 days)
Trial: 7438324
Drug: Hyperfractionation (HF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionation (HF) with misonidazole (2 g/m2 daily doses, total dose 14 g/m2 over 35 days)
Trial: 31251892
Drug: RPE-guided aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RPE-guided aerobic training (n=11; 16 weeks, 20 min, twice weekly at RPE 3-6)
Trial: 27577177
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (POMx), 2 capsules of 250 mg per day for 8 weeks
Trial: 27577177
Drug: Cellulose (control),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose (control), 2 capsules of 250 mg per day for 8 weeks
Trial: 26176930
Drug: sham tDCS/escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham tDCS/escitalopram 20 mg/day
Trial: 26176930
Drug: sham tDCS/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham tDCS/placebo pill
Trial: 22717170
Drug: l‐tryptophan (2.8g/d)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐tryptophan (2.8g/d)
Trial: 22358274
Drug: TENS (Transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS (Transcutaneous Electrical Nerve Stimulation) applied for 30 minutes, three times a day, along with analgesic therapy and physiotherapy.
Trial: 22358274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received more physiotherapy analgesic therapy without TENS.
Trial: 18327706
Drug: Aprepitant-based regimen
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant-based regimen (day 1: aprepitant 125 mg, ondansetron 8 mg, dexamethasone 12 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: aprepitant 80 mg qd)
Trial: 18327706
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (day 1: ondansetron 8 mg and dexamethasone 20 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: ondansetron 8 mg bid)
Trial: 15033400
Drug: Yasmin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yasmin (30 microg ethinylestradiol + 3 mg drospirenone)
Trial: 11793859
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CSA) at an initial dosage of 5 mg.kg‐1.d‐1, gradually tailed off over three months and maintained at 2 mg.kg‐1.d‐1 for 12 months.
Trial: 11793859
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) at a dosage of 37.5 mg/day.
Trial: 8063043
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of the ACTH4-9 analogue ORG 2766 every 24 h
Trial: 3281838
Drug: Sodium meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium meglumine ioxaglate (320 or 306 mg I/ml)
Trial: 3281838
Drug: Meglumine diatrizoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine diatrizoate (306 mg I/ml)
Trial: 28760121
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TA) 10 mg/kg 20 minutes preoperatively and 3 hours after first dose
Trial: 28760121
Drug: Intra-articular tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular tranexamic acid (TA) 3 g locally into surgical site
Trial: 18363581
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (150 mg, 3 times daily for 1 week after each blood donation)
Trial: 16492219
Drug: Glibenclamide (5.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5.25 mg)
Trial: 12671696
Drug: Active lozenges
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active lozenges (PTA) containing polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg, four times daily during radiotherapy
Trial: 12671696
Drug: Placebo lozenges,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges, four times daily during radiotherapy
Trial: 12671696
Drug: Active lozenges
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active lozenges (PTA)
Trial: 8938220
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cyclophosphamide and methotrexate followed by concomitant 5-fluorouracil and irradiation
Trial: 30574609
Drug: Intensive oral
RxNorm normalized name: Uricalm Intensive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive oral care programme (IOCP)
Trial: 26000622
Drug: Active music
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active music therapy (MT) in addition to speech language therapy (SLT)
Trial: 26000622
Drug: Speech language
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech language therapy (SLT) alone
Trial: 25151488
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg daily during radiation therapy
Trial: 21389934
Drug: Levetiracetam (keppra)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (keppra) as first monotherapy
Trial: 21389934
Drug: Levetiracetam (keppra)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (keppra) as second or third monotherapy
Trial: 17803835
Drug: Brief eclectic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief eclectic psychotherapy (BEP) in 16 weekly individual sessions
Trial: 11890650
Drug: Etanercept (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (TNF inhibitor)
Trial: 11890650
Drug: Infliximab (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (TNF inhibitor)
Trial: 3283292
Drug: Moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (450 mg daily in three divided doses)
Trial: 27920262
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise programme filmed on an electronic tablet with automated reminders (n=30)
Trial: 19074207
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea catechin beverage (625 mg of catechins with 39 mg caffeine)
Trial: 19074207
Drug: Control beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control beverage (39 mg caffeine, no catechins)
Trial: 11564123
Drug: Levetiracetam 1,000
RxNorm normalized name: Levetiracetam 1,000mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1,000 mg/day
Trial: 11564123
Drug: Levetiracetam 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 2,000 mg/day
Trial: 9040320
Drug: 5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms of the new hepatitis B vaccine
Trial: 9040320
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of the new hepatitis B vaccine
Trial: 9040320
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of the new hepatitis B vaccine
Trial: 9040320
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms of the new hepatitis B vaccine
Trial: 9040320
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of the new hepatitis B vaccine (single dose)
Trial: 2976406
Drug: Acitretin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (30 mg/day initial dose for 4 weeks, mean dose 30.7 mg/day at end of study)
Trial: 2976406
Drug: Etretinate (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (initial dose not specified, mean dose 33.4 mg/day at end of study)
Trial: 27264224
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg subcutaneous injections
Trial: 27264224
Drug: Placebo subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injections
Trial: 22948196
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 2 L of 0.9% saline
Trial: 22948196
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 2 L of 0.9% saline
Trial: 21191426
Drug: Combination niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination niacin extended-release + simvastatin (NER/S)
Trial: 18762754
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 microg kg(‐1) as bolus before induction and 0.2 microg kg(‐1) h(‐1) by infusion
Trial: 18762754
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 microg kg(‐1) as bolus before induction and 0.5 microg kg(‐1) h(‐1) by infusion
Trial: 15915020
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg intravenous droperidol
Trial: 15915020
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intravenous droperidol
Trial: 9856967
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg moxonidine
Trial: 2744779
Drug: Salbutamol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (8 mg slow release twice daily)
Trial: 2744779
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg twice daily)
Trial: 984352
Drug: Pentobarbitone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone (100 mg) given orally
Trial: 984352
Drug: Pentobarbitone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone (100 mg) given intramuscularly
Trial: 984352
Drug: Pentobarbitone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone (100 mg) organic preparation (Nembutal)
Trial: 984352
Drug: Pentobarbitone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone (100 mg) aqueous solution
Trial: 984352
Drug: Pentobarbitone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone (100 mg) injected by doctors
Trial: 984352
Drug: Pentobarbitone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone (100 mg) injected by nurses
Trial: 25092211
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion of ropivacaine (2 mL/hour of 0.375% ropivacaine after initial 10 mL of 0.75% ropivacaine)
Trial: 25092211
Drug: Intermittent epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent epidural ropivacaine (10 mL of 0.75% ropivacaine followed by 10 mL of 0.2% ropivacaine every 6 hours)
Trial: 22075651
Drug: Psychodynamic interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic interpersonal therapy (PIT), 12 weekly sessions
Trial: 22075651
Drug: Psychodynamic interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic interpersonal therapy (PIT)
Trial: 20977840
Drug: Ultra-micronized BYHWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-micronized BYHWD (5 g, twice a day) for 12 weeks
Trial: 20977840
Drug: Traditional BYHWD
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional BYHWD (15 g, twice a day) for 12 weeks
Trial: 8466735
Drug: Isradipine SRO
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine SRO at 2.5 mg/day (increased to 5 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Trial: 8466735
Drug: Enalapril at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril at 10 mg/day (increased to 20 mg/day if DBP remained above 90 mm Hg after 4 weeks)
Trial: 30111378
Drug: Immediate prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prophylactic application of incisional Negative-pressure Wound Therapy (iNPWT) following ILND
Trial: 25444821
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (PCV-9)
Trial: 7830214
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment condition
Trial: 25523633
Drug: Anagliptin (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagliptin (100mg twice daily)
Trial: 25523633
Drug: Sitagliptin (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100mg once daily)
Trial: 19573436
Drug: High amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High amino acid group (HP): 2.4 g/(kg.d) of amino acid IV within 24 hours after birth
Trial: 16159869
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg body weight for 6 days
Trial: 11579299
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with ATG
Trial: 11579299
Drug: Immediate tacrolimus-based
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate tacrolimus-based triple therapy
Trial: 9585718
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 60 mg/day for 7 weeks)
Trial: 9585718
Drug: Nortriptyline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (3 weeks treatment)